verteporfin and ranibizumab

PreclinicalMonoclonal antibody

verteporfin and ranibizumab is one of 6 small molecule programs targeting Polypoidal choroidal vasculopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polypoidal Choroidal VasculopathyActive, not recruiting

Polypoidal Choroidal VasculopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Polypoidal Choroidal Vasculopathy

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

6 2

Vabysmo

Roche

Approved

2 3

Kenalog

BBausch Health Americas, Inc.

Approved

1 4

Visudyne

BBausch Health Americas, Inc.

Preclinical

1 5

Intravitreal Bevacizumab

AAsociación para Evitar la Ceguera en México

Preclinical

1 6

verteporfin and ranibizumab

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polypoidal choroidal vasculopathy1 trial

Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

Completed·SSun Yat-sen University·N/A·NCT03459144·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for verteporfin and ranibizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — verteporfin and ranibizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for verteporfin and ranibizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: SSun Yat-sen University

verteporfin and ranibizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polypoidal choroidal vasculopathy1 trial

References

Drug Info

Quick Facts

Related News